Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia
Go back to Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia| (NASDAQ: NAGE) | Delayed: 2.99 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.99 | 52 Week High | $ | |||
| Open | $2.99 | 52 Week Low | $ | |||
| Day High | $3.03 | P/E | N/A | |||
| Day Low | $2.97 | EPS | $ | |||
| Volume | 609,163 | |||||
